Literature DB >> 8899844

Permeation of buprenorphine and its 3-alkyl-ester prodrugs through human skin.

A L Stinchcomb1, A Paliwal, R Dua, H Imoto, R W Woodard, G L Flynn.   

Abstract

PURPOSE: Homologous 3-alkyl-ester prodrugs (C2 to C4) of buprenorphine with decreased crystallinity have been synthesized and evaluated for transdermal delivery commensurate with opioid dependence treatment.
METHODS: To assess the influence of derivatization on delivery, the permeation of the prodrugs through human skin was determined in vitro. Prodrug metabolism was measured in human blood and skin supernatant in vitro along with chemical hydrolysis controls. The prodrugs octanol/water partition coefficients were measured.
RESULTS: Without exception, the prodrugs were completely hydrolyzed on passing through the skin and appeared as buprenorphine in the receptor compartment. However, using saturation conditions, in no instance did the buprenorphine flux through skin from a prodrug solution exceed the flux of buprenorphine base itself in vitro. Moreover, the flux of the acetyl ester, the least hydrophobic of the prodrugs, was not significantly elevated upon stripping the skin. Whether in blood or the skin supernatant, the prodrugs hydrolyzed in an apparent first-order fashion and rate constants and half-lives were calculated.
CONCLUSIONS: We conclude from the results that the prodrugs' very high octanol/water partition coefficients (hydrophobicity) placed them in viable tissue layer controlled diffusion. Consequently, one does not derive the potential flux-increasing benefit of reducing crystallinity that was expected.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8899844     DOI: 10.1023/a:1016079513007

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  7 in total

1.  A controlled trial of buprenorphine treatment for opioid dependence.

Authors:  R E Johnson; J H Jaffe; P J Fudala
Journal:  JAMA       Date:  1992-05-27       Impact factor: 56.272

2.  Reports from research centres--16. The National Institute on Drug Abuse (NIDA).

Authors:  C R Schuster
Journal:  Br J Addict       Date:  1989-01

3.  Correlation and prediction of mass transport across membranes. I. Influence of alkyl chain length on flux-determining properties of barrier and diffusant.

Authors:  G L Flynn; S H Yalkowsky
Journal:  J Pharm Sci       Date:  1972-06       Impact factor: 3.534

4.  A solubility and related physicochemical property comparison of buprenorphine and its 3-alkyl esters.

Authors:  A L Stinchcomb; R Dua; A Paliwal; R W Woodard; G L Flynn
Journal:  Pharm Res       Date:  1995-10       Impact factor: 4.200

5.  Transdermal delivery of buprenorphine through cadaver skin.

Authors:  S D Roy; E Roos; K Sharma
Journal:  J Pharm Sci       Date:  1994-02       Impact factor: 3.534

6.  Permeation of hairless mouse skin II: membrane sectioning techniques and influence on alkanol permeabilities.

Authors:  G L Flynn; H Dürrheim; W I Higuchi
Journal:  J Pharm Sci       Date:  1981-01       Impact factor: 3.534

7.  Maintenance of skin viability during in vitro percutaneous absorption/metabolism studies.

Authors:  S W Collier; N M Sheikh; A Sakr; J L Lichtin; R F Stewart; R L Bronaugh
Journal:  Toxicol Appl Pharmacol       Date:  1989-07       Impact factor: 4.219

  7 in total
  6 in total

Review 1.  Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.

Authors:  Alexander Elkader; Beth Sproule
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Reversible dimers of the atypical antipsychotic quetiapine inhibit p-glycoprotein-mediated efflux in vitro with increased binding affinity and in situ at the blood-brain barrier.

Authors:  Dana Emmert; Christopher R Campos; David Ward; Peihua Lu; Hilda A Namanja; Kelsey Bohn; David S Miller; Frances J Sharom; Jean Chmielewski; Christine A Hrycyna
Journal:  ACS Chem Neurosci       Date:  2014-02-07       Impact factor: 4.418

3.  Topical iontophoresis of valaciclovir hydrochloride improves cutaneous aciclovir delivery.

Authors:  Nada Abla; Aarti Naik; Richard H Guy; Yogeshvar N Kalia
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

Review 4.  Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl.

Authors:  S Grond; L Radbruch; K A Lehmann
Journal:  Clin Pharmacokinet       Date:  2000-01       Impact factor: 6.447

5.  Topical delivery of a model phenolic drug: alkyloxycarbonyl prodrugs of acetaminophen.

Authors:  Scott C Wasdo; Kenneth B Sloan
Journal:  Pharm Res       Date:  2004-06       Impact factor: 4.200

Review 6.  A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain.

Authors:  Jeffrey Gudin; Jeffrey Fudin
Journal:  Pain Ther       Date:  2020-01-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.